When the math says go but the court says no, what happens next?
In pharma, that question is no longer theoreticalits operational. Drug launches are timed like financial instruments: the window is narrow, the burn rate is real, and the downside is often…
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Evergreen-ing is the headline everybody usesright up until you try to separate marketing from mechanics.
In a world where a single branded medicine can generate billions in revenue, the patent system becomes more than a legal framework. It becomes stra…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
The quiet ROI of suing early: Why weak method-of-use patents are often the best place to start
Patent litigation in pharma has a reputation for being expensive, slow, and ugly. But thats only half the story.
The other half is happening quietlyinside th…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
If youve been anywhere near generic drug strategy, youve heard it: win the first-to-file race and you get 180 days of exclusivity. It sounds like a built-in moattime to recoup R&a…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Drug patent settlements are treated like a foregone conclusion in life sciencesan expensive but rational exit ramp once litigation begins. But that reflex can be dangerously lazy. The real question isnt whether settlement is common; its whether its eco…
A device patent challenge often doesnt start with the biggest cracksit starts with the weakest wall.
In pharma, its easy to think of a patent portfolio as a fortress: layered, fortified, and designed to keep generic competition at bay. But litigation a…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The Salt Change Trap: When a New Patent Buys You Nothing
Pharmaceutical patents are supposed to protect breakthroughsnot reroute competition through legal shell games. But in recent years, a quiet strategy has become increasingly common: the salt chang…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Pediatric exclusivity was sold as a shield. In practice, its becoming a liability.
Imagine youre a drug developer trying to navigate a thicket of timelines, clinical requirements, and regulatory incentivesonly to find that a single policy designed to h…
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Bausch + the burden of proof: what no, it wasnt obvious really looks like in a modern patent case
If youve ever wondered whats actually at stake when a pharma patent dispute heads to court, this case is a reminder that the fight isnt just about drugsit…
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Exelixis vs. Intas: When Generic Isnt a WordIts a Strategy
Theres a recurring misunderstanding in biotech: that generic competition is a straight linepatents fall, approvals follow, prices drop.
In reality, the biotech IP battleground is often a labyri…
Get new actionable insights and updates from BiotechBlog
